AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11709566 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 698
Study 11709566 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy
Number of subjects: 698
Study 9304332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal immunization with inactivated influenza vaccine (IIV)
Number of subjects: 856
Study 9304332 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunization)
Number of subjects: 856
Study 8105790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene augmentation
Number of subjects: 11
Study 3301925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional fluorouracil (1 ml of 50 mg/ml)
Number of subjects: 11
Study 3301925 — intervention group
Group type: COMPARATOR
Intervention: Control lesions (no treatment)
Number of subjects: 11
Study 3301925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional fluorouracil
Number of subjects: 11
Study 30870576 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate (4 mg doses, two annual doses)
Number of subjects: 25
Study 30870576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 30223447 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D₃ supplementation (5000 IU/day)
Number of subjects: 25
Study 30223447 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 25
Study 26678102 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable plates/screws (group A)
Number of subjects: 27
Study 26678102 — intervention group
Group type: COMPARATOR
Intervention: Titanium plates/screws (group B)
Number of subjects: 27
Study 26678102 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 27
Study 24768894 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress task (Trier Social Stress Test)
Number of subjects: 54
Study 24768894 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 54
Study 24768894 — intervention group
Group type: EXPERIMENTAL
Intervention: High inhibitory control
Number of subjects: 54
Study 24768894 — intervention group
Group type: EXPERIMENTAL
Intervention: A-typical hunger stress response
Number of subjects: 54
Study 23072964 — intervention group
Group type: EXPERIMENTAL
Intervention: CI only
Number of subjects: 9
Study 23072964 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal conditions
Number of subjects: 9
Study 23072964 — intervention group
Group type: COMPARATOR
Intervention: LFT-on
Number of subjects: 9
Study 23072964 — intervention group
Group type: COMPARATOR
Intervention: LFT-off
Number of subjects: 9
Study 21510461 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (50 mg) + Metformin (500 mg) bid/tid (n=115)
Number of subjects: 229
Study 21510461 — intervention group
Group type: COMPARATOR
Intervention: Metformin (500 mg) bid/tid (n=114)
Number of subjects: 229
Study 18637534 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc therapy
Number of subjects: 0
Study 15956865 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-based screening
Number of subjects: 473
Study 15956865 — intervention group
Group type: COMPARATOR
Intervention: Interview-based screening
Number of subjects: 473
Study 12616661 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5% (Lidoderm)
Number of subjects: 0
Study 12616661 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended application of lidocaine patch 5%
Number of subjects: 0
Study 12616661 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous application of up to four patches per day
Number of subjects: 0
Study 10623695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg administered intravenously every month
Number of subjects: 0
Study 10623695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8646314 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction unit
Number of subjects: 0
Study 8646314 — intervention group
Group type: COMPARATOR
Intervention: Control group (no computer-assisted instruction)
Number of subjects: 0
Study 1355981 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-adrenoceptor blockade with phentolamine
Number of subjects: 7
Study 1355981 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined alpha-adrenoceptor, beta-adrenoceptor (propranolol) and parasympathetic (atropine) blockade
Number of subjects: 7
Study 6386481 — intervention group
Group type: EXPERIMENTAL
Intervention: miniheparin (2 X 2500 IU daily)‐dihydroergotamine
Number of subjects: 50
Study 6386481 — intervention group
Group type: COMPARATOR
Intervention: conventional low‐dose heparin
Number of subjects: 50
Study 6386481 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 3091407 — intervention group
Group type: EXPERIMENTAL
Intervention: Monash protocol (RWH patients)
Number of subjects: 60
Study 3091407 — intervention group
Group type: COMPARATOR
Intervention: RWH control (RWH patients)
Number of subjects: 60
Study 3091407 — intervention group
Group type: EXPERIMENTAL
Intervention: RWH protocol (Monash patients)
Number of subjects: 60
Study 3091407 — intervention group
Group type: COMPARATOR
Intervention: Monash control (Monash patients)
Number of subjects: 60
Study 29898793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia (CBT-I)
Number of subjects: 0
Study 29898793 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training (active control)
Number of subjects: 0
Study 28386791 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS)
Number of subjects: 0
Study 28386791 — intervention group
Group type: COMPARATOR
Intervention: Conventional risk score (CRS)
Number of subjects: 0
Study 26354539 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef ingestion (30 g protein)
Number of subjects: 12
Study 26354539 — intervention group
Group type: COMPARATOR
Intervention: Milk ingestion (30 g protein)
Number of subjects: 12
Study 23301686 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone PR 10 mg + Naloxone PR 5 mg
Number of subjects: 85
Study 23301686 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone PR 10 mg
Number of subjects: 85
Study 21085590 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitizers
Number of subjects: 36
Study 21085590 — intervention group
Group type: COMPARATOR
Intervention: Fluctuating subjects
Number of subjects: 36
Study 21085590 — intervention group
Group type: COMPARATOR
Intervention: Repressors
Number of subjects: 36
Study 17926079 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA and Photofrin fluorescence-guided resection and repetitive photodynamic therapy (PDT)
Number of subjects: 27
Study 17926079 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 27
Study 17926079 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA and Photofrin fluorescence-guided resection and repetitive PDT
Number of subjects: 27
Study 17132752 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide treatment
Number of subjects: 52
Study 17132752 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 52
Study 12477613 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored three-step decision-aid
Number of subjects: 289
Study 9819045 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of factor VIII (FVIII) concentrates
Number of subjects: 13
Study 9819045 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of factor IX (FIX) concentrates
Number of subjects: 13
Study 9819045 — intervention group
Group type: COMPARATOR
Intervention: Control non-haemophilic patients with heparin prophylaxis
Number of subjects: 13
Study 9819045 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus dose of 50 U/kg of a very high purity clotting factor concentrate
Number of subjects: 13
Study 7659762 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine (oral administration before learning)
Number of subjects: 0
Study 7659762 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine (intramuscular injection after learning)
Number of subjects: 0
Study 7659762 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine (during the 1st hour after learning)
Number of subjects: 0
Study 7659762 — intervention group
Group type: COMPARATOR
Intervention: General arousal or attentional processes
Number of subjects: 0
Study 2757893 — intervention group
Group type: EXPERIMENTAL
Intervention: 155 mg oral tablet of hydroxychloroquine
Number of subjects: 5
Study 2757893 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of 155 mg racemic hydroxychloroquine
Number of subjects: 5
Study 334473 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg flurbiprofen 3-times daily for 3 weeks
Number of subjects: 14
Study 334473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 334473 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint scanning of 99mTc uptake
Number of subjects: 14
Study 30647912 — intervention group
Group type: EXPERIMENTAL
Intervention: DSF combined with nutritional copper supplement (DSF-Cu) as an adjuvant to alkylating chemotherapy
Number of subjects: 142
Study 30647912 — intervention group
Group type: COMPARATOR
Intervention: Control group without DSF-Cu
Number of subjects: 142
Study 27209501 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone whole-breast irradiation
Number of subjects: 100
Study 27209501 — intervention group
Group type: COMPARATOR
Intervention: Supine whole-breast irradiation
Number of subjects: 100
Study 24399871 — intervention group
Group type: COMPARATOR
Intervention: Whole Body Vibration (WBV) training
Number of subjects: 0
Study 24399871 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 0
Study 24399871 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit resistance training
Number of subjects: 0
Study 24399871 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body strength
Number of subjects: 0
Study 22173608 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP combined with chemotherapy
Number of subjects: 76
Study 22173608 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 76
Study 20512501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling (20 min sub-maximal cycling in an upright position with relaxed shoulders)
Number of subjects: 25
Study 18641114 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous aspiration of subglottic secretions (CASS)
Number of subjects: 714
Study 15730579 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple decompression
Number of subjects: 0
Study 15730579 — intervention group
Group type: COMPARATOR
Intervention: Anterior subcutaneous transposition
Number of subjects: 0
Study 12939125 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intervention to increase consumption of fruit and vegetables to at least five portions per day (received by intervention participants).
Number of subjects: 729
Study 12939125 — intervention group
Group type: COMPARATOR
Intervention: Control group (received the same intervention after 6 months).
Number of subjects: 729
Study 10363570 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 31
Study 10363570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 7862546 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw relaxation
Number of subjects: 84
Study 7862546 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 84
Study 7862546 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of relaxation and music
Number of subjects: 84
Study 7862546 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study 7862546 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw relaxation and music (combined)
Number of subjects: 84
Study 2127044 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT mixture (50% MCT and 50% LCT)
Number of subjects: 24
Study 2127044 — intervention group
Group type: COMPARATOR
Intervention: LCT (long-chain triglycerides)
Number of subjects: 24
Study 7420563 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day treatment with penicillin-G
Number of subjects: 60
Study 7420563 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day treatment with trimethoprim-sulfamethoxazole
Number of subjects: 60
Study 7420563 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole
Number of subjects: 60
Study 7420563 — intervention group
Group type: COMPARATOR
Intervention: 10-day treatment
Number of subjects: 60
Study 7420563 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day regimen
Number of subjects: 60
Study 31596655 — intervention group
Group type: EXPERIMENTAL
Intervention: Test‐snack
Number of subjects: 17
Study 31596655 — intervention group
Group type: COMPARATOR
Intervention: Control‐snack
Number of subjects: 17
Study 31596655 — intervention group
Group type: COMPARATOR
Intervention: Bread
Number of subjects: 17
Study 31539171 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.05% vaginal cleansing
Number of subjects: 320
Study 31539171 — intervention group
Group type: COMPARATOR
Intervention: No cleansing (control)
Number of subjects: 320
Study 28969509 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of orange-fleshed sweet potato (OFSP)
Number of subjects: 295
Study 28969509 — intervention group
Group type: EXPERIMENTAL
Intervention: Household production of OFSP
Number of subjects: 295
Study 28969509 — intervention group
Group type: EXPERIMENTAL
Intervention: Purchasing of OFSP
Number of subjects: 295
Study 28969509 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge on health benefits of OFSP
Number of subjects: 295
Study 28969509 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of children aged less than 5 years
Number of subjects: 295
Study 28969509 — intervention group
Group type: EXPERIMENTAL
Intervention: Production of OFSP
Number of subjects: 295
Study 27377450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy for Recovery of Self-Esteem (CBGTRS), 12 group sessions
Number of subjects: 62
Study 27377450 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study 24329187 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 2.5 mg
Number of subjects: 25
Study 22267373 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 5 mg daily for 5 days
Number of subjects: 106
Study 22267373 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate 100 mg daily for 5 days
Number of subjects: 106
Study 20479349 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 90‐minute team skills training sessions
Number of subjects: 0
Study 17564197 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory information agreeing with vision (group 1)
Number of subjects: 0
Study 17564197 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory information agreeing with proprioception (group 2)
Number of subjects: 0
Study 17564197 — intervention group
Group type: COMPARATOR
Intervention: No auditory information (group 3)
Number of subjects: 0
Study 16109821 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence based prevention programme including educational activities and recommendations
Number of subjects: 644
Study 16109821 — intervention group
Group type: COMPARATOR
Intervention: Comparison departments (control)
Number of subjects: 644
Study 16109821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention activities
Number of subjects: 644
Study 16109821 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of skin problems
Number of subjects: 644
Study 12685522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin LA, Metadate CD, Concerta, Adderall XR (new long-acting formulations of MPH and AMP)
Number of subjects: 0
Study 12685522 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus delivery (BD) and controlled delivery (CD) processes used in drug delivery systems
Number of subjects: 0
Study 12685522 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory School Protocol (LSP)
Number of subjects: 0
Study 10987232 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and radiotherapy (lumpectomy and axillary dissection followed by external beam radiotherapy)
Number of subjects: 266
Study 10987232 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 266
Study 10987232 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of axillary dissection (number of nodes retrieved)
Number of subjects: 266
Study 8690115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine-rebound method
Number of subjects: 0
Study 8690115 — intervention group
Group type: COMPARATOR
Intervention: Long protocol
Number of subjects: 0
Study 1866002 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg dipyridamole and 330 mg acetylsalicylic acid tid
Number of subjects: 2500
Study 1866002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study 7102534 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol, 10 mg twice a day (n = 7)
Number of subjects: 24
Study 7102534 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, median dose 80 mg three times a day (n = 9)
Number of subjects: 24
Study 7102534 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol, 150 mg twice a day (n = 8)
Number of subjects: 24
Study 31943195 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 0
Study 31943195 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 0
Study 31943195 — intervention group
Group type: COMPARATOR
Intervention: Lasmiditan (phase 3)
Number of subjects: 0
Study 31282306 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR) of 2% body mass
Number of subjects: 15
Study 27987040 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 60 mg (AT60, n=16)
Number of subjects: 30
Study 27987040 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg (AT20, n=14)
Number of subjects: 30
Study 27987040 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with atorvastatin (both doses)
Number of subjects: 30
Study 27987040 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaques with ACS
Number of subjects: 30
Study 27987040 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaques with stable angina
Number of subjects: 30
Study 27009449 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (0.625 mg/0.025 ml)
Number of subjects: 79
Study 27009449 — intervention group
Group type: COMPARATOR
Intervention: Conventional indirect laser therapy
Number of subjects: 79
Study 24487616 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (16.5 kcal/kg/week of aerobic exercise, three times per week)
Number of subjects: 26
Study 24487616 — intervention group
Group type: COMPARATOR
Intervention: Control (treatment as usual, no exercise)
Number of subjects: 26
Study 23046818 — intervention group
Group type: EXPERIMENTAL
Intervention: COACH programme delivered by primary care physicians assisted by nurse educators (PCP-NE)
Number of subjects: 297
Study 23046818 — intervention group
Group type: COMPARATOR
Intervention: COACH programme delivered by primary care physicians (PCP) alone
Number of subjects: 297
Study 20181239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive oriented consultation offered two weeks after injury (intervention group).
Number of subjects: 326
Study 20181239 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 326
Study 17321110 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (10 mg, three times weekly for 6 months)
Number of subjects: 46
Study 17321110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 16263618 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed treatment
Number of subjects: 127
Study 16263618 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 127
Study 11904101 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic lymphatic filariasis patients
Number of subjects: 0
Study 11904101 — intervention group
Group type: COMPARATOR
Intervention: Controls (non-affected individuals)
Number of subjects: 0
Study 10451081 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal muscle strengthening exercise and back education
Number of subjects: 402
Study 10451081 — intervention group
Group type: COMPARATOR
Intervention: Back education only
Number of subjects: 402
Study 8287870 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine 6 mg
Number of subjects: 20
Study 8287870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3323261 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 151
Study 3323261 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 151
Study 31242079 — intervention group
Group type: EXPERIMENTAL
Intervention: HDC/IL-2
Number of subjects: 0
Study 29706442 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional stretching exercises, 3 times a week for 4 weeks
Number of subjects: 45
Study 29706442 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional stretching exercises
Number of subjects: 45
Study 27387325 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once daily
Number of subjects: 120
Study 27387325 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 75 mg/m² for six cycles
Number of subjects: 120
Study 24664649 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated treatment
Number of subjects: 245
Study 24664649 — intervention group
Group type: COMPARATOR
Intervention: Physician-initiated treatment
Number of subjects: 245
Study 22151696 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depression
Number of subjects: 5869
Study 20071644 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (2 g purified EPA/DHA)
Number of subjects: 34
Study 20071644 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 34
Study 18033153 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (Strattera)
Number of subjects: 3000
Study 15902529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum Gram stain, culture, and detection of pneumococcal antigen
Number of subjects: 262
Study 15902529 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary pneumococcal antigen test
Number of subjects: 262